News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 6, 2024

A New Era in PAH Treatment?

Author(s)Marius Hoeper, MD

An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.

Episodes in this series

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 1 Evolving Guidelines for PAH Treatment

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 2 New Therapeutic Frontiers in PAH

Ioana Preston, MD, a pulmonologist

EP. 3 Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

Ioana Preston, MD, a pulmonologist

EP. 4 Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

Marius Hoeper, MD, an expert on PAH

EP. 5 Breaking Down the PAH Cost Burden

Marius Hoeper, MD, an expert on PAH

EP. 6 A New Era in PAH Treatment?

"Clinical Evidence for Emerging PAH Therapies"

EP. 7 Clinical Evidence for Emerging PAH Therapies

"Integrating New PAH Therapies into Clinical Practice"

EP. 8 Integrating New PAH Therapies into Clinical Practice

Ioana Preston, MD, a pulmonologist

EP. 9 Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 10 FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 11 Overcoming Barriers to Better Patient Outcomes in PAH

Ioana Preston, MD, a pulmonologist

EP. 12 Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

Marius Hoeper, MD, an expert on PAH

EP. 13 Optimizing PAH Care Delivery for Better Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 14 Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following question:

What is your assessment of the potential clinical impact of new or emerging pulmonary arterial hypertension (PAH) therapies, such as sotatercept, ralinepag, and inhaled imatinib, in terms of reducing hospitalizations or need for supportive care and improving long-term patient outcomes and quality of life?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Investing in the Future: Redesigning Healthcare Infrastructure for CRM Excellence

ByIan J. Neeland, MD

June 16th 2026

From Reactive to Proactive: Evolving Health Systems for CRM Management

ByIan J. Neeland, MD

June 16th 2026

Foundational Therapy Approaches to Mitigate Long-Term CRM Complications

ByIan J. Neeland, MD

June 9th 2026

Bridging the Disconnect: From Diagnosis to Treatment in Cardio-Renal-Metabolic Syndrome

ByIan J. Neeland, MD

June 9th 2026

2 experts in this video

Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy

ByEdward Skolnik, MD ,Swati Arora, MD

March 6th 2026

Trending on AJMC

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM

Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk

As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning

FAQ: Prior Authorization Reform—Will Changes Go Far Enough by 2027?